Epygenix Therapeutics
140 E. Ridgewood Avenue South Tower, Suite #415
Paramus
New Jersey
07652
United States
Tel: 201-940-7377
Fax: 201-940-7218
Website: http://epygenix.com/
Email: info@epygenix.com
About Epygenix Therapeutics
Epygenix Therapeutics, Inc. is a precision medicine-based biopharmaceutical company developing drugs to treat rare and intractable genetic epilepsise, such as Dravet syndrome, Lennox- Gastaut syndrome, and etc.
7 articles about Epygenix Therapeutics
-
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
-
Epygenix Therapeutics Announces Appointment of Dr. Lorianne Masuoka as Chief Medical Officer
5/23/2022
Epygenix Therapeutics, a clinical-stage biopharmaceutical company developing safe, effective, and patient-friendly drugs for rare and intractable forms of genetic epilepsy, announces the appointment of Lorianne Masuoka, MD as Chief Medical Officer.
-
Biopharma and life sciences companies continue to strengthen their executive teams and boards with this week’s Movers & Shakers.
-
Epygenix Therapeutics Successfully Completes EPX-100 Phase I, Placebo-Controlled, Double-Blind, 2-Period Study and Ready to Phase 2 Studies
1/27/2020
Epygenix Therapeutics, Inc. announced that the Company successfully completed a Phase I, Placebo-Controlled, Double-Blind, 2-Period Study to assess safety and pharmacokinetics of escalating single and multiple oral doses of EPX-100 in fasting healthy subjects and following a high-fat meal.
-
Epygenix Therapeutics Receives US FDA Orphan Drug Designation For EPX-300 For The Treatment Of Patients With Dravet Syndrome
8/23/2017
-
Epygenix Therapeutics Receives Orphan Drug Designation From The U.S. FDA For EPX-100 And EPX-200 In The Treatment Of Patients With Dravet Syndrome
4/25/2017